Prognostic significance of pretreatment 18F-FDG PET/CT in hepatocellular carcinoma: A systematic review and meta-analysis

  • Min, Ji Hye; 
  • Rezaee-Zavareh, Mohammad Saeid; 
  • Attia, Abdelrahman M.; 
  • Hwang, Soo Young; 
  • Chen, Pin-Jung; 
  • 외 7명
Citations

WEB OF SCIENCE

1
Citations

SCOPUS

1

초록

Background & Aims: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is not routinely recommended for hepatocellular carcinoma (HCC) diagnosis or surveillance, and its prognostic role in patients with HCC remains unclear. This meta-analysis aims to evaluate the prognostic significance of 18F-FDG PET/CT in HCC. Methods: A systematic literature search was conducted until August 2024 to identify studies evaluating the prognostic value of 18F-FDG PET/CT in patients with HCC. Studies were included if they reported an association between pre-treatment PET/CT and clinical outcomes, including overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS). A random-effects model was employed with heterogeneity assessed using the I2 statistic. Results: We identified 59 relevant studies (6 prospective and 53 retrospective) including 8,585 patients. Pre-treatment 18F-FDG PET/CT was positive in 30.8% of patients with HCC. Increased FDG activity was associated with poorer OS (hazard ratio [HR] 2.05, 95% CI 1.77-2.38, I2 = 71.6%), RFS (HR 3.18, 95% CI 2.08-4.86, I2 = 96.8%), and PFS (HR 1.64, 95% CI 1.36-1.98, I2 = 71.8%), respectively. FDG activity was significantly associated with OS for both curative (HR 2.10, 95% CI 1.58-2.80, I2 = 62%) and non-curative (HR 2.28, 95% CI 1.59-3.25, I2 = 75.3%) treatments. The prognostic significance of 18F-FDG PET/CT remained consistent across various PET/CT parameters, including SUVmax, tumor-to-liver ratio, and visual assessment of PET/CT positivity, and curative/non-curative therapeutic modalities, all demonstrating that higher FDG uptake is associated with poorer clinical outcomes. Conclusions: Pre-treatment 18F-FDG PET/CT is positive in 30.8% of patients with HCC and is significantly associated with adverse clinical outcomes. These findings support its prognostic relevance in HCC, while further studies may help refine its clinical role and standardize 18F-FDG PET/CT-based risk stratification. PROSPERO ID: CRD42025633333. (c) 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

키워드

Metabolic imaging; Risk stratification; Imaging biomarker; Survival; Recurrence; POSITRON-EMISSION-TOMOGRAPHY; METABOLIC TUMOR VOLUME; F-18-FDG PET; LIVER-TRANSPLANTATION; TRANSARTERIAL CHEMOEMBOLIZATION; F-18-FLUORODEOXYGLUCOSE UPTAKE; ALPHA-FETOPROTEIN; PREDICTIVE-VALUE; EARLY RECURRENCE; SURVIVAL
제목
Prognostic significance of pretreatment 18F-FDG PET/CT in hepatocellular carcinoma: A systematic review and meta-analysis
저자
Min, Ji Hye; Rezaee-Zavareh, Mohammad Saeid; Attia, Abdelrahman M.; Hwang, Soo Young; Chen, Pin-Jung; Yalda, Tamar; Adetyan, Hasmik; Hemadeh, Rami; Kim, Hyun-seok; Taouli, Bachir; Singal, Amit G.; Yang, Ju Dong
DOI
10.1016/j.jhepr.2026.101901
발행일
2026-08
유형
Review
저널명
JHEP Reports
권
8
호
8